TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more
TaiMed Biologics (4147) - Total Liabilities
Latest total liabilities as of September 2025: NT$896.74 Million TWD
Based on the latest financial reports, TaiMed Biologics (4147) has total liabilities worth NT$896.74 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TaiMed Biologics - Total Liabilities Trend (2009–2024)
This chart illustrates how TaiMed Biologics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TaiMed Biologics Competitors by Total Liabilities
The table below lists competitors of TaiMed Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Foosung
KO:093370
|
Korea | ₩499.67 Billion |
|
Foresee Pharmaceuticals Co Ltd
TWO:6576
|
Taiwan | NT$593.99 Million |
|
Jiangsu Boiln Plastics Co. Ltd.
SHE:301003
|
China | CN¥59.26 Million |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
USA | $13.54 Million |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
USA | $10.14 Million |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
India | ₹15.63 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down TaiMed Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TaiMed Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TaiMed Biologics (2009–2024)
The table below shows the annual total liabilities of TaiMed Biologics from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$976.34 Million | -26.47% |
| 2023-12-31 | NT$1.33 Billion | -4.21% |
| 2022-12-31 | NT$1.39 Billion | -16.96% |
| 2021-12-31 | NT$1.67 Billion | -6.25% |
| 2020-12-31 | NT$1.78 Billion | +55.58% |
| 2019-12-31 | NT$1.14 Billion | +61.05% |
| 2018-12-31 | NT$710.55 Million | +237.22% |
| 2017-12-31 | NT$210.71 Million | +139.48% |
| 2016-12-31 | NT$87.99 Million | +230.38% |
| 2015-12-31 | NT$26.63 Million | -47.11% |
| 2014-12-31 | NT$50.35 Million | -11.66% |
| 2013-12-31 | NT$56.99 Million | +300.43% |
| 2012-12-31 | NT$14.23 Million | -6.04% |
| 2011-12-31 | NT$15.15 Million | -10.24% |
| 2010-12-31 | NT$16.88 Million | -11.55% |
| 2009-12-31 | NT$19.08 Million | -- |